Volume Alert - ACT 261.24 Actavis Inc $ACT Hit a high today

New Post Public Reply Private Reply Replies (0) Message Board
leahanne
Volume Alert - ACT 261.24 Actavis Inc $ACT Hit a high today of 264.00 Closing the day 10:30 at 261.24 +13.30 +5.36% With a day low of 249.86 and a total volume of 4,598,087.

ACT Recent Posts: http://investorshangout.com/Actavis-Inc-ACT-53105/

ACT Actavis Inc Recent Headline News

Actavis (ACT) Is Today's Unusual Social Activity Stock
at The Street - 14 mins ago
Trade-Ideas LLC identified Actavis (ACT) as an unusual social activity candidate
ACT: 260.23 (+12.29)

One Factor Driving Up Actavis (ACT) Stock Today
at The Street - 22 mins ago
Actavis (ACT) shares continue to climb as analysts at Citigroup (C) raised the company's price target following its purchase of Allergan (AGN) for $66 billion.
ACT: 260.33 (+12.39)

Stock Market News for November 18, 2014 - Market News
Zacks Equity Research - Zacks Investment Research - 1 hr 18 mins ago
Markets ended its choppy run yesterday on a mixed note after Japan unexpectedly slipped into a recession
AGN: 212.10 (+2.90), ACT: 260.33 (+12.39), EOG: 97.17 (+0.82), HAL: 49.59 (+0.36), HP: 77.44 (-0.81), MRO: 31.90 (+0.08), BHI: 65.76 (+0.53)

Will Pfizer's Dividend Be Safe?
Todd Campbell, The Motley Fool - Motley Fool - 1 hr 59 mins ago
Source: Pfizer via Facebook. Pfizer (NYSE: PFE) may be one of the planet's largest drugmakers, but it's been navigating a series of sales-crunching patent expirations that has investors wondering if the company's dividend payout will remain...
ACT: 260.33 (+12.39), PFE: 30.57 (+0.25), TEVA: 57.44 (+0.20)

Winners And Losers In The Allergan Valeant Actavis Melee; Also, Will Bill Ackman Lose His Profit?
Uncommon Profit Investor - at Seeking Alpha - 2 hrs 55 mins ago

AGN: 212.00 (+2.80), VRX: 141.24 (+4.51), ACT: 260.33 (+12.39)

Here Are Some Big Caps Poised To Make Gains
at Investor's Business Daily - Mon Nov 17, 5:45PM CST
Several Big Cap 20 stocks have recently broken out of bases, but are still within buy range, or are building new bases and could be good additions to a watch list. Alexion Pharmaceuticals (ALXN) has pulled back and is within the 5% buy zone. The...
AGN: 212.00 (+2.80), ACT: 260.33 (+12.39), VRX: 141.24 (+4.51), V: 250.52 (+0.72), ALXN: 190.26 (+3.48), CTSH: 52.76 (-0.30), MA: 83.66 (+0.46), ADS: 282.56 (+1.68)

Bristol-Myers Squibb Reports Positive Opdivo Phase III Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 17, 5:20PM CST
Bristol-Myers Squibb Company announced encouraging data from the phase III CheckMate - 066 study on immuno-oncology drug Opdivo.
AGN: 212.00 (+2.80), ACT: 260.33 (+12.39), AMAG: 36.27 (+1.51), BMY: 58.69 (+0.26)

After Hour Gainers / Losers
Seeking Alpha - at Seeking Alpha - Mon Nov 17, 4:40PM CST

URBN: 27.99 (-2.84), DHX: 11.32 (+0.06), ACT: 260.33 (+12.39), OME: 12.43 (-2.55), CLVS: 53.47 (+0.14), AVB: 158.37 (+0.21), PF: 32.42 (-1.30), RMTI: 10.31 (-0.27), GLW: 20.45 (+0.09), FOLD: 6.33 (-0.37)


Actavis to spend $66 billion on Allergan
By TOM MURPHY - AP - Mon Nov 17, 4:01PM CST
Actavis, which is buying Botox-maker Allergan for $66 billion in one of the biggest acquisitions announced so far this year, plans to stay committed to developing new products.
1 Comment
DRTX: 24.16 (+0.41), AGN: 212.00 (+2.80), ACT: 260.33 (+12.39), VRX: 141.24 (+4.51), MRK: 59.86 (+0.40), VRX.TO: 159.70 (+5.30)

Stocks End Mixed As Allergan Jumps On Actavis Deal
at Investor's Business Daily - Mon Nov 17, 3:16PM CST
Major averages pared losses from a late-morning slump to end mixed amid big merger deals and weak economic data. The S&P 500 and Dow Jones industrial average closed fractionally higher, while the Nasdaq fell 0.4%. Volume ran lower across the board in...
AGN: 212.00 (+2.80), VRX: 141.24 (+4.51), ACT: 260.33 (+12.39), SAFM: 86.42 (+1.49), PPC: 31.21 (+0.27), MIK: 21.99 (+0.34), TSN: 42.31 (-0.72)

Stock Market Today: Japan Recession Keeps Markets From Celebrating Deals Deluge
at The Street - Mon Nov 17, 3:15PM CST
Wheelings and dealings from top pharmaceutical giants and energy companies momentarily distracts Wall Street from worrying news Japan has fallen into recession in its third quarter.
AMZN: 327.57 (+4.52), HAS: 55.97 (-0.40), ACT: 260.33 (+12.39), VRX: 141.24 (+4.51), JIVE: 6.41 (+0.04), FB: 74.37 (+0.13), HAL: 49.60 (+0.37), DWA: 22.18 (-0.13), AGN: 212.00 (+2.80), LNKD: 224.68 (+1.40), BHI: 65.75 (+0.52), CRM: 63.02 (+0.51)

Stocks Mixed In Afternoon; Allergan Jumps To New High
at Investor's Business Daily - Mon Nov 17, 2:13PM CST
Stocks remained mixed late Monday afternoon as investors weighed a spate of merger activity against news that Japan fell into a recession. The Dow Jones industrial average and the S&P 500 were each up 0.1%, while the Nasdaq was down 0.3%. Volume was...
AGN: 212.00 (+2.80), VRX: 141.24 (+4.51), ACT: 260.33 (+12.39), LNKD: 224.68 (+1.40), FB: 74.37 (+0.13), HAL: 49.60 (+0.37), BHI: 65.75 (+0.52), Z: 117.43 (-0.43)

Stock Market Today: Stocks Are Mixed as Corporate Deals Offset Japan's Recession
at The Street - Mon Nov 17, 12:16PM CST
Wheelings and dealings from top pharmaceutical giants and energy companies distract Wall Street from worrying news Japan had fallen into recession in its third quarter.
AGN: 212.00 (+2.80), HAS: 55.97 (-0.40), AMZN: 327.57 (+4.52), VRX: 141.24 (+4.51), ACT: 260.33 (+12.39), LNKD: 224.68 (+1.40), JIVE: 6.41 (+0.04), FB: 74.36 (+0.12), HAL: 49.60 (+0.37), DWA: 22.18 (-0.13), CRM: 63.02 (+0.51), BHI: 65.75 (+0.52)

Pershing Square wins big on Actavis buy
Seeking Alpha - at Seeking Alpha - Mon Nov 17, 11:22AM CST

AGN: 212.00 (+2.80), ACT: 260.33 (+12.39), VRX: 141.24 (+4.51)

Cramer: Investors Should Ignore Analysts' Calls on Hotel, Other Stocks
at The Street - Mon Nov 17, 10:32AM CST
Analysts have been growing pessimistic on several high quality stocks and sectors. Investors should use weakness as a buying opportunity instead, Cramer said.
AGN: 212.00 (+2.80), ACT: 260.33 (+12.39), PG: 87.96 (+0.12), MAR: 76.71 (-0.46), HOT: 77.41 (+0.56)

Allergan's $66 Billion Actavis Deal is Still a Win for Bill Ackman
at The Street - Mon Nov 17, 9:59AM CST
Valeant says it can't justify $219 a share offer to shareholders.
ZTS: 43.65 (-0.58), AGN: 212.00 (+2.80), VRX: 141.24 (+4.51), ACT: 260.33 (+12.39)

Stock Market Today: Stocks Shrug Off Japan's Recession as Deals Dominate Day
at The Street - Mon Nov 17, 9:40AM CST
U.S. stocks recover from earlier lows triggered by Japan's recession. Deals news about Baker Hughes and Allergan dominate headlines.
AGN: 212.00 (+2.80), HAS: 55.97 (-0.40), ACT: 260.33 (+12.39), HAL: 49.60 (+0.37), DWA: 22.18 (-0.13), BHI: 65.75 (+0.52)

ALLERGAN, INC. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation Of Buyout
PR Newswire - Mon Nov 17, 9:32AM CST
Rigrodsky & Long, P.A.:
AGN: 212.00 (+2.80), ACT: 260.33 (+12.39)

Actavis Nabs Allergan For $66 Billion; Valeant Folds
at Investor's Business Daily - Mon Nov 17, 9:17AM CST
One of the most widely rumored deals in pharma came to fruition Monday, as Actavis (ACT) agreed to acquire Allergan (AGN) for $66 billion in cash and stock. Allergan stock was up more than 7%, near 213, and Actavis stock up nearly 4%, near 253, in...
AGN: 212.00 (+2.80), VRX: 141.24 (+4.51), ACT: 260.33 (+12.39)

Time to move on: Valeant chief says $219 too rich
Seeking Alpha - at Seeking Alpha - Mon Nov 17, 9:13AM CST

ACT: 260.33 (+12.39), VRX: 141.24 (+4.51)
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Aluminum Design Fumble: Geometry Over Wall Thickness

Updated Category News Views 135

A Misstep in Aluminum Design Practices Well, here's a nugget of wisdom for the metal enthusiasts out there—stop beefing up aluminum components with thicker walls and focus on smart geometry. This isn't a drill, folks. Mark Coyle, a seasoned mind over at American Custom Metals, has been waving the flag for smarter aluminum design methods right from Rochester, NY, and...

Continue Reading
Bio-Thera's New Data: A Game Changer for NSCLC?

Updated Category News Views 239

A Fresh Look at Lung Cancer Solutions There's fresh meat on the oncology block, with Bio-Thera Solutions swinging for the fences at ESMO 2026, spotlighting promising Phase 2 clinical data for their combo treatment in first-line non-small cell lung cancer (NSCLC). If you're tuned into the biopharmaceutical sector or just keeping tabs on global health romps, this news sets...

Continue Reading
World Young Scientist Summit 2026 in Wenzhou Kicks Off

Updated Category News Views 154

Young Minds Meet AI Innovation Crack open the playbook, and it's clear: young brains from across the globe are gathering in Wenzhou, Zhejiang, China, to wrangle with AI and chart the course of science toward a sustainable future. The World Young Scientist Summit 2026 isn't just a parade of speeches and accolades. Nah, it's a deep dive into where innovative minds believe...

Continue Reading
ST Engineering iDirect, MBSat Forge Middle East Satellite Hub

Updated Category News Views 0

Satellite Services Take Off in the Middle East Never thought the day would come where the Middle East is on the threshold of leapfrogging satellite tech, but here we are. ST Engineering iDirect just locked arms with MBSat—yep, that's part of the Mohammed Al Barwani Group—to birth a next-gen satellite connectivity service hub in Oman and across surrounding areas....

Continue Reading
Taiwan Fuses Ancient TCM with Modern Bio Tech in 2026

Updated Category News Views 170

The Dynamic Fusion of Heritage and Innovation When you think about it, mixing centuries-old herbal wisdom with today's cutting-edge biotech might sound like a plot twist, but that's exactly what's cooking in Taiwan. Over at SupplySide Global 2026 in Las Vegas, Taiwan's got something more than just traditional medicine to flaunt; it's showcasing an impressive fusion of...

Continue Reading
Spooky Dining at CARNE: A Halloween Hit in Oxnard

Updated Category News Views 158

A Festive Transformation at CARNE Rolling into Oxnard, you're met with an unconventional dining spectacle at CARNE. It's not your average restaurant fare as they've pulled out the stops with their spirited Halloween pop-up, A Nightmare at CARNE. Channeling the eerie charm of "The Nightmare Before Christmas," this temporary transformation morphs the venue into a lively,...

Continue Reading
Swanson Nexus Pro Launch: Boost for Dietitians

Updated Category News Views 184

Swanson Enters the Education Arena for Nutritionists Swanson Vitamins is mixing things up again! This time, they're launching something called Swanson Vitamins Nexus Pro, aimed squarely at the registered dietitians and licensed nutritionists crowd. Starting out as the place to grab your basic vitamins, Swanson's not resting on their supplement laurels. No, siree. They've...

Continue Reading
Axon Body 5: A Leap Forward in AI for Public Safety

Updated Category News Views 270

Axon Raises the Stakes with Body 5 Camera Boy, oh boy, Axon's dropped a bombshell with the Body 5. We're talking a colossal leap into the AI era for public safety, and if you're in the biz, you can't just shrug this one off. We're looking at 25 times the AI processing power compared to Axon's old units. That's right, I said twenty-five. Real-time situational awareness in...

Continue Reading
Amgen's IMDELLTRA® Shows Promise in SCLC Battle

Updated Category News Views 328

Breakthrough Results in SCLC Treatment For years, small cell lung cancer (SCLC) has been the unruly beast in the oncology world, defying treatment advances and keeping survival rates stubbornly low. This nasty foe might just have met its match, folks. Amgen (NASDAQ:AMGN) announced results from their Phase 3 DeLLphi-305 trial that show their drug IMDELLTRA®, when teamed...

Continue Reading
Wenda Pharma's NHWD-870 HCl Shows Promise in Trial

Updated Category News Views 141

Breaking Through in NUT Carcinoma Treatment Imagine battling an aggressive disease with barely any options left, and then something hopeful shows up in the pipeline. That's the story with Zhejiang Wenda Pharma's NHWD-870 HCl, an oral BET inhibitor making waves at the 2026 ESMO Annual Meeting. Facing off against the nasty beast that is NUT carcinoma, this drug didn't just...

Continue Reading

Top 5 Most Recently Viewed Articles

Senator Whitehouse Addresses Challenges in Climate Summit Attendance

Updated Category News Views 330

Senator Whitehouse's Message on Climate Action Sen. Sheldon Whitehouse emphasized a direct message at this year's U.N. climate summit. He assured global negotiators that the United States remains dedicated to climate action, despite the challenges faced during the Trump administration. Challenges at the U.N. Climate Summit Whitehouse specifically pointed out internal...

Continue Reading
The Surge of Spearmint Oil: Insights on Market Growth to 2033

Updated Category News Views 125

Growing Potential of the Spearmint Oil Market Allied Market Research has revealed exciting projections for the spearmint oil market, anticipating it will escalate from a valuation of $180.1 million in recent years to an impressive $377.5 million by 2033, all the while attaining a compound annual growth rate (CAGR) of 7.7% from 2024 to 2033. Factors Fueling Market...

Continue Reading
Exploring Adobe's Stock Growth Track Record Over Two Decades

Updated Category News Views 212

Adobe Stock: A 20-Year Investment Journey Adobe Inc (NASDAQ: ADBE) has demonstrated exceptional stock performance over the past twenty years, consistently outpacing market averages by 5.02% annually. This remarkable growth culminates in an average annual return of 13.66%, showcasing the strength of Adobe’s business model and innovative contributions to the tech...

Continue Reading
Virginia Housing Program Expands Access with New Limits

Updated Category News Views 187

Virginia Housing Introduces New Income and Sales Price Limits Recently, Virginia Housing announced significant updates regarding the maximum gross household income and sales price limits for homebuyers. This change is destined to benefit numerous first-time and repeat homebuyers across the state of Virginia. With these updates, a wider range of individuals and families...

Continue Reading
DraftKings Poised for Strong Growth in Revenue and Earnings

Updated Category News Views 219

Analysts Optimistic About DraftKings' Future Growth DraftKings Inc (NASDAQ: DKNG) is garnering attention as analysts assess the company's outlook for 2025 following its recent fourth-quarter results. Industry experts are weighing in on the potential for substantial growth in revenue and earnings, indicating a positive trajectory for the company. Strong Analyst Ratings...

Continue Reading